CRCristina Roqueta

Cristina Roqueta

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Cristina Roqueta has a total of 36 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Assessment tools addressing avoidable care transitions in older adults: a systematic literature review

    by Rustem Makhmutov, Alicia Calle Egusquiza, Cristina Roqueta Guillen, Eva-Maria Amor Fernandez, Gabriele Meyer, Moriah E. Ellen, Steffen Fleischer, Anna Renom Guiteras

    Purpose: The phenomenon of avoidable care transitions has received increasing attention over the last decades due to its frequency and associated burden for the patients and the healthcare system. A number of assessment tools to identify avoidable transitions have been designed and implemented. The selection of the most appropriate tool appears to be challenging and time-consuming. This systematic review aimed to identify and comprehensively describe the assessment tools that can support stakeholders´ care transition decisions on older adults. Methods: This study was conducted as part of the TRANS-SENIOR research network. A systematic search was conducted in MEDLINE via PubMed, CINAHL, and CENTRAL. No restrictions regarding publication date and language were applied. Results: The search in three electronic databases revealed 1266 references and screening for eligibility resulted in 58 articles for inclusion. A total of 48 assessment tools were identified covering different concepts, judgement processes, and transition destinations. We found variation in the comprehensiveness of the tools with regard to dimensions used in the judgement process. Conclusion: All tools are not comprehensive with respect to the dimensions covered, as they address only one or a few perspectives. Although assessment tools can be useful in clinical practice, it is worth it to bear in mind that they are meant to support decision-making and supplement the care professional´s judgement, instead of replacing it. Our review might guide clinicians and researchers in choosing the right tool for identification of avoidable care transitions, and thus support informed decision-making.


  • Open Access

    Risk Factors Associated with the Mortality of COVID-19 Patients Aged ≥60 Years Neither Intubated nor Treated with Mechanical Ventilation: A Multicentre Retrospective Cohort Study during the First Wave in Spain

    by Dante R. Culqui, Josep Ortega Segura, Elisabeth Da Costa-Venancio, Anna Renom-Guiteras, Esther Roquer, Sherly Melissa Muñoz Tejada, Patricia Rodriguez, Adilis L. Alba Travieso, Isis Medrano, Lizzeth Canchucaja-Gutarra, et al.

    Background: To determine risk factors of death in diagnosed patients with COVID-19 who were aged ≥60 years and could not benefit from intubation and mechanical ventilation. Methods: Retrospective multicentre study including all patients with COVID-19 admitted to four medium-stay centres in Catalonia (March-June 2020). At the multivariate level, we calculated hazard ratios (HR) with 95% confidence intervals (CI) to determine risk factors associated with mortality. Results: 683 patients were included, of whom 227 died (case fatality rate of 33%, reaching 42% in patients of more than 90 years). Mean survival was 21.92 (20.98–22.86) days. Factors associated with death were fever (HR:1.5 (1.06–2.13)), malaise (HR:1.4 (1.04–1.99)), dyspnoea (HR:1.98 (1.41–2.79)) and atrial fibrillation (HR:1.45 (1.03–2.05)), while coughing (HR: 0.66 (0.46–0.94)), diarrhoea (HR:0.46 (0.23–0.92)), dyslipidaemia (HR:0.47 (0.28–0.82)), and receiving antithrombotic treatment (HR:0.56 (0.40–0.78)) had a protective effect. The analysis by age group showed that other factors were uniquely associated with each age group, such as chronic obstructive pulmonary disease at 60–74 years and polypharmacy at 75–90 years, among other factors. Conclusions: Case fatality in COVID-19 patients who could not benefit from intubation and mechanical ventilation was exceptional. Clinical manifestations such as fever, malaise, dyspnoea and atrial fibrillation helped to identify patients at higher risk of mortality, while antithrombotic treatment had a protective effect. Although some symptoms are very general regarding COVID-19, in the context of the first wave without vaccination, when not much was known about the disease, such symptoms could be useful.


  • Open Access

    Quality of Life in Older Patients after a Heart Failure Hospitalization: Results from the SENECOR Study

    by Daniele Luiso, Marta Herrero-Torrus, Neus Badosa, Cristina Roqueta, Sonia Ruiz-Bustillo, Laia C. Belarte-Tornero, Sandra Valdivielso-Moré, Ronald O. Morales, Olga Vázquez, Núria Farré

    Background: Information about health-related quality of life (HRQoL) in heart failure (HF) in older adults is scarce. Methods: We aimed to describe the HRQoL of the SENECOR study cohort, a single-center, randomized trial comparing the effects of multidisciplinary intervention by a geriatrician and a cardiologist (intervention group) to that of a cardiologist alone (control group) in older patients with a recent HF hospitalization. Results: HRQoL was assessed by the short version of the disease-specific Kansas Cardiomyopathy Questionnaire (KCCQ-12) in 141 patients at baseline and was impaired (KCCQ-12 < 75) in almost half of the cohort. Women comprised 50% of the population, the mean age was 82.2 years, and two-thirds of patients had preserved ejection fraction. Comorbidities were highly prevalent. Patients with impaired HRQoL had a worse NYHA functional class, a lower NT-proBNP, a lower Barthel index, and a higher Clinical Frailty Scale. One-year all-cause mortality was 22.7%, significantly lower in the group with good-to-excellent HRQoL (14.5% vs. 30.6%; hazard ratio 0.28; 95% confidence interval 0.10–0.78; p = 0.014). In the group with better HRQoL, all-cause hospitalization was lower, and there was a trend towards lower HF hospitalization. Conclusions: The KCCQ-12 questionnaire can provide inexpensive prognostic information even in older patients with HF. (Funded by grant Primitivo de la Vega, Fundación MAPFRE. ClinicalTrials number, NCT03555318).


  • Open Access

    Randomized Controlled Trial Comparing a Multidisciplinary Intervention by a Geriatrician and a Cardiologist to Usual Care after a Heart Failure Hospitalization in Older Patients: The SENECOR Study

    by Marta Herrero-Torrus, Neus Badosa, Cristina Roqueta, Sonia Ruiz-Bustillo, Eduard Solé-González, Laia C. Belarte-Tornero, Sandra Valdivielso-Moré, Olga Vázquez, Núria Farré

    Background: The prognosis of older patients after a heart failure (HF) hospitalization is poor. Methods: In this randomized trial, we consecutively assigned 150 patients 75 years old or older with a recent heart failure hospitalization to follow-up by a cardiologist (control) or follow-up by a cardiologist and a geriatrician (intervention). The primary outcome was all-cause hospitalization at a one-year follow-up. Results: All-cause hospitalization occurred in 47 of 75 patients (62.7%) in the intervention group and in 58 of 75 patients (77.3%) in the control group (hazard ratio, 0.67; 95% confidence interval, 0.46 to 0.99; p = 0.046). The number of patients with at least one HF hospitalization was similar in both groups (34.7% in the intervention group vs. 40% in the control group, p = 0.5). There were a total of 236 hospitalizations during the study period. The main reasons for hospitalization were heart failure (38.1%) and infection (14.8%). Mortality was 24.7%. Heart failure was the leading cause of mortality (54.1% of all deaths), without differences between groups. Conclusions: A follow-up by a cardiologist and geriatrician in older patients after an HF hospitalization was superior to a cardiologist’s follow-up in reducing all-cause hospitalization in older patients. (Funded by Beca Primitivo de la Vega, Fundación MAPFRE. ClinicalTrials.gov number, NCT03555318).